Man Group
KYMR icon

Man Group’s Kymera Therapeutics KYMR Stock Holding History

Man Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
19,085
+5,751
+43% +$494K ﹤0.01% 1528
2026
Q1 		$1.11M Sell
13,334
-6,692
-33% -$530K ﹤0.01% 1798
2025
Q4 		$1.56M Buy
+20,026
New +$1.35M ﹤0.01% 1544
2022
Q4 		– Sell
-26,550
Closed -$578K – 2103
2022
Q3 		$578K Buy
+26,550
New +$700K ﹤0.01% 1476
2022
Q2 		– Hold
0
– – – 1572

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Man Group's KYMR Position: Q2 2026 in Review

Man Group increased its Kymera Therapeutics (KYMR) stake by 43% in Q2 2026, buying an estimated $494K and bringing the position to 19,085 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Man Group first reported a position in KYMR in Q3 2022 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Man Group held 19,085 shares of Kymera Therapeutics worth $2.19M as of Q2 2026.
  • Man Group bought 5,751 Kymera Therapeutics shares in Q2 2026, an estimated $494K.
  • Kymera Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1528 holding.
  • Man Group first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.